Bringing the fundamentals into focus…
Back to Recursion Pharmaceuticals, Inc.
How Recursion Pharmaceuticals, Inc. stacks up
RXRX · against 404 other Healthcare companies of similar size
Overall
24/ 100
Near the bottom of its peers.
Ranked #376 of 405 · scores higher than 6% of peers
Bars: peers in each 10-point band of the overall score37 peers with an overall score of 20–29, including RXRX · Click a bar to see the companies
The four scores behind it
Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)Ranking by overall score
Top 5 and the companies ranked around RXRX| Rank | Company | Market cap | Overall | Valuation | Growth | Profitability | Risk |
|---|---|---|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | 100 | 0 / 2 | ||
| 2 | 2.1B USD | 96 | 96 | 99 | 93 | 0 / 2 | |
| 2 | 15.6B DKK (≈$2.3B) | 96 | 96 | 99 | 96 | 0 / 2 | |
| 4 | 1.5B USD | 93 | 94 | 91 | 93 | 0 / 2 | |
| 5 | 2.29T KRW (≈$1.6B) | 88 | 83 | 90 | 96 | 0 / 2 | |
| 370 | 2.0B USD | 26 | 8 | 56 | 14 | 2 / 2 | |
| 375 | 2.3B USD | 25 | 8 | 0 | 4 | 0 / 2 | |
| 376 | 3.7B USD | 24 | 8 | 9 | 1 | 0 / 2 | |
| 376 | 1.6B USD | 24 | 8 | 63 | 16 | 2 / 2 | |
| 376 | 2.0B USD | 24 | 8 | 17 | 3 | 0 / 2 | |
| 376 | 1.2B USD | 24 | 8 | 53 | 30 | 2 / 2 | |
| 380 | 14.8B CNY (≈$2.1B) | 23 | 0 | 6 | 32 | 1 / 2 | |
| 380 | 1.7B USD | 23 | 8 | 5 | 3 | 0 / 2 | |
| 380 | 2.2B USD | 23 | 8 | 21 | 21 | 1 / 2 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score